Cargando…
Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for India’s public sector
BACKGROUND: Truenat is a novel molecular assay that rapidly detects tuberculosis (TB) and rifampicin-resistance. Due to the portability of its battery-powered testing platform, it may be valuable in peripheral healthcare settings in India. METHODS: Using a microsimulation model, we compared four TB...
Autores principales: | Lee, David J., Kumarasamy, Nagalingeswaran, Resch, Stephen C., Sivaramakrishnan, Gomathi N., Mayer, Kenneth H., Tripathy, Srikanth, Paltiel, A. David, Freedberg, Kenneth A., Reddy, Krishna P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6605662/ https://www.ncbi.nlm.nih.gov/pubmed/31265470 http://dx.doi.org/10.1371/journal.pone.0218890 |
Ejemplares similares
-
2000. Rapid, Point-of-care Diagnosis of Tuberculosis with Novel Truenat Assay: Cost-Effectiveness and Budgetary Impact Analysis for India’s Public Sector
por: Lee, David J, et al.
Publicado: (2018) -
A prospective multicentre diagnostic accuracy study for the Truenat tuberculosis assays
por: Penn-Nicholson, Adam, et al.
Publicado: (2021) -
The cost‐effectiveness and budgetary impact of a dolutegravir‐based regimen as first‐line treatment of HIV infection in India
por: Zheng, Amy, et al.
Publicado: (2018) -
Performance evaluation of Truenat™ Beta CoV & Truenat™ SARS-CoV-2 point-of-care assays for coronavirus disease 2019
por: Basawarajappa, Shantala Gowdara, et al.
Publicado: (2021) -
Diagnostic accuracy of Truenat Tuberculosis and Rifampicin-Resistance assays in Addis Ababa, Ethiopia
por: Meaza, Abyot, et al.
Publicado: (2021)